NCT06681064Recruiting
Breast Cancer Evolution During Neoadjuvant Systemic Therapy
Source: ClinicalTrials.gov · Last updated 16 Apr 2026
Brief summary (registry, in English)
BELIEVE is a translational research study that aims to collect samples of breast cancer tissue and blood from individuals undergoing breast cancer treatment (such as chemotherapy, targeted therapy and immunotherapy) before surgery. In certain cases, MRI scans and stool samples will also be obtained before and during treatment. The samples collected from this study will be used for molecular and genetic research to understand why some cancers respond very well to anticancer treatments, and some do not, develop novel ways of accurately measuring response during treatment, as well as identify which patients are at a higher risk of the cancer coming back after surgery.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 500 (estimated)
- First submitted
- 5 Nov 2024
- Start date
- 29 May 2024
- Primary completion date
- May 2034
- Lead sponsor
- Royal Marsden NHS Foundation Trust
- Diseases
- Triple-negative breast cancer
- NCT number
- NCT06681064
What you commit to
- Study type: Observational
- Planned participants: 500
- From 29 May 2024 to the primary completion date, May 2034
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Treatment with neoadjuvant endocrine therapy only.
Other illness
- Metastatic breast cancer at diagnosis.
- Presence of any psychological, familial or sociological condition potentially hampering compliance with the study protocol and follow-up schedule.
Who the study is looking for
- Histologically confirmed non-metastatic invasive breast cancer.
- Be suitable for, but have not commenced, neoadjuvant chemotherapy, targeted therapy, or immunotherapy.
- If HER2-, suitable for treatment with upfront taxane chemotherapy. If HER2+, suitable for treatment with anti-HER2 targeted therapy.
- Be aged 18 years and over.
- Have given written informed consent to participate.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Royal Marsden NHS Foundation Trust Coordinator of this site? Confirm its status | London | United Kingdom | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.